AZAYA THERAPEUTICS

Azaya Therapeutics, Inc

From:	President & CEO
Date:	12 Aug 2014

Eugene and Dmytro - We did it! We have a product!

On Friday, August 8, we had 3 significant events occur. Our primary focus for the past 4 years has been to test our product, ATI-0918, against the branded drug, DOXIL/CAELYX. Among other tests, we were required to conduct a 48 patient clinical trial that has been ongoing for the past 21 months.

- *We began this clinical study back in November 2012 In the US and Canada and expanded the study to Ukraine in November 2013. We now have the satisfaction of seeing the study come to a successful completion. We completed treating the last patient in the clinical trial in Ukraine in late June 2014. We completed all of the patient blood sample testing and data verification and locked the data base on Friday. This is a major milestone for the regulatory approval of this product.*
- *More importantly on Friday night we received the results of the study from our central lab, MicroConstants in San Diego, and the data proved that the two products, ATH0918 and Caelyx, are Bioequivalent. This was the regulatory endpoint for this study, and we can now initiate the final steps needed to file for centralized regulatory approval in the European Union. We are waiting for a FDA determination in September 2014 on the final steps for filing for approval in the US.*

All of us at Azaya thank you for your efforts on our behalf in helping us create this success. We look forward to our next study in Ukraine…

Best regards

President & CEO
Azaya Therapeutics, Inc.